Mostrar el registro sencillo del ítem

dc.contributor.authorCuevas, Oscar
dc.contributor.authorCercenado, Emilia
dc.contributor.authorVindel, Ana
dc.contributor.authorGuinea, Jesus
dc.contributor.authorSanchez-Conde, Matilde
dc.contributor.authorSanchez-Somolino, Mar
dc.contributor.authorBouza, Emilio
dc.date.accessioned2024-02-06T15:24:41Z
dc.date.available2024-02-06T15:24:41Z
dc.date.issued2004-11-01
dc.identifier.issn0066-4804
dc.identifier.otherhttps://journals.asm.org/journal/aaces
dc.identifier.urihttp://hdl.handle.net/20.500.12020/1282
dc.description.abstractData regarding the evolution of Staphylococcus resistance in a whole country have a definite influence on the design of empirical treatment regimens. Nevertheless, incidence studies over long periods of time are expensive and very difficult to carry out. In order to ascertain the present situation of the antimicrobial resistance of Staphylococcus in Spain and the change of this resistance over time, we performed five point prevalence studies (1986 to 2002) in a large group of Spanish hospitals (from 68 institutions in 1986 to 143 in 2002) collecting all Staphylococcus strains isolated on a single selected day. All microorganisms were identified in the five studies at the same laboratory, and antimicrobial susceptibility testing was performed against 17 antimicrobial agents by the agar dilution method and a microdilution method. During this period, there was an overall increase in resistance to most antimicrobials among Staphylococcus aureus/coagulase-negative staphylococci, mainly to oxacillin (1.5%/32.5% in 1986 versus 31.2%/61.3% in 2002) (P < 0.001), erythromycin (7%/41.1% in 1986 versus 31.7%/63% in 2002) (P < 0.001), gentamicin (5.2%/25.4% in 1986 versus 16.9%/27.8% in 2002) (P < 0.001; P   0.5), and ciprofloxacin (0.6%/1.1% in 1986 versus 33.9%/44.9% in 2002) (P < 0.001). All of the isolates were uniformly susceptible to glycopeptides, linezolid, and quinupristin/dalfopristin. Resistance of S. aureus to trimethoprim/sulfamethoxazole was very low (from 0.5% to 2.1%) (P   0.152). Periodic performance of prevalence studies is a useful, inexpensive, and easy tool to know the nationwide situation of a microorganism and its resistance to antimicrobials; it also helps us assess the emergence and spread of antimicrobial resistance.es
dc.language.isoenes
dc.publisherAmerican Society for Microbiologyes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEvolution of the Antimicrobial Resistance of Staphylococcus spp. in Spain: Five Nationwide Prevalence Studies, 1986 to 2002es
dc.typearticlees
dc.identifier.doi10.1128/AAC.48.11.4240–4245.2004
dc.issue.number11es
dc.journal.titleAntimicrobial Agents and Chemotherapyes
dc.page.initial4240es
dc.page.final4245es
dc.relation.projectIDThis work was supported in part by “Red Espan˜ola de Investigación en Patología Infecciosa ” (REIPI-ISCIII-C03/14). We are grateful to AVENTIS for financing the transport of sampleses
dc.rights.accessRightsembargoedAccesses
dc.subject.areaCiencias Biomédicases
dc.subject.keywordStaphylococcal Infectionses
dc.subject.keyworddrug therapyes
dc.subject.keywordepidemiologyes
dc.subject.keywordMicrobiologyes
dc.subject.unesco3201.03 Microbiología Clínicaes
dc.volume.number48es


Ficheros en el ítem

Fichero/sTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional